INAB
INAB
NASDAQ · Biotechnology

In8Bio Inc

$1.99
+0.09 (+4.74%)
As of Feb 8, 2:24 PM ET ·
Analyst Consensus
Strong Buy
9
Analysts
Moderate
Coverage
Buy 8 89%
Hold 1 11%
Sell 0 0%
Price Target
Analyst Price Target +1,939.2% upside
Low Target $25.27
Average Target $40.58
High Target $56.74
Current Price $1.99
Current
$1.99
Target
$40.58
$25.27 $40.58 avg $56.74
Scenario Analysis
Bear Case
$25.27
1,169.8%
Low target
Base Case
$40.58
+1,939.2%
Avg target
Bull Case
$56.74
+2,751.3%
High target
Risk/Reward
2.4x
Favorable
Price in Context
52-Week High
$35.81
-94.4% from high
52-Week Low
$29.00
+-93.1% from low
Target vs 52W High
$40.58
+13.3% vs high
Next Earnings Report
Mar 2, 2026 · After Market Close
14d
until earnings
EPS Est: $-0.63
Earnings in 14 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Buy 37 68% $257.58 +15.3%
AMGN
Amgen Inc
Hold 41 54% $190.87 -50.3%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +137.8%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 77% $438.34 -8.3%
REGN
Regeneron Pharmaceuticals
Strong Buy 36 75% $76.80 -90.2%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 75% $102.31 -68.8%
INSM
Insmed Inc
Strong Buy 27 93% $143.40 -4.3%
BIIB
Biogen Inc
Hold 42 48% $91.45 -54.5%